Columbia neuroscientists have identified a genetic mutation that fends off Alzheimer's in people at high risk and could lead to a new way to protect people from the disease.
With funding from the Ultra-rare Gene-based Therapy Network, scientists at Columbia and the n-Lorem Foundation will create tailor-made gene-based therapies for people with rare forms of ALS.
A study led by Columbia and Cornell researchers finds, surprisingly, that anticoagulants do not prevent recurrent strokes in people with one type of heart condition.
Using EEG to identify covert consciousness in unresponsive brain-injured patients could help predict which ones may recover, find researchers at Columbia and NewYork-Presbyterian.
Research from Scott Small's lab at Columbia University suggests a different approach to tackling the disease, and a new startup company is now trying to turn that approach into treatments.
A gene called FMNL2 may explain why people with hypertension, diabetes, heart disease, or obesity have a greater risk of developing Alzheimer's disease.
A transient ischemic attack (TIA) is a stroke that usually lasts under five minutes and resolves on its own, but just because the symptoms disappear, does not mean a TIA should be ignored.
A new initiative led by Columbia University and the n-Lorem Foundation will develop personalized therapies for individuals with "nano-rare" genetic forms of ALS and treat them for free, for life.
Parkinson’s patients and their families are increasingly turning to genetic testing to learn more about their disease or risk of passing it on. But testing is complex, and counseling is advised.
COVID patients who remain unresponsive after receiving respiratory support may require long time periods to regain consciousness; delays are related to blood oxygen levels.